The estimated Net Worth of Shawn Cross is at least $677 Thousand dollars as of 22 November 2023. Mr Cross owns over 110,802 units of Applied Molecular Transport stock worth over $141,830 and over the last 4 years he sold AMTI stock worth over $82,160. In addition, he makes $453,499 as Chief Financial Officer at Applied Molecular Transport.
Sign up
Mr Cross AMTI stock SEC Form 4 insiders trading
Mr has made over 9 trades of the Applied Molecular Transport stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 110,802 units of AMTI stock worth $17,728 on 22 November 2023.
The largest trade he's ever made was selling 193,960 units of Applied Molecular Transport stock on 28 September 2023 worth over $31,034. On average, Mr trades about 23,356 units every 46 days since 2021. As of 22 November 2023 he still owns at least 545,499 units of Applied Molecular Transport stock.
You can see the complete history of Mr Cross stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Shawn M. Cross biography
Shawn M. Cross is the Chief Financial Officer at Applied Molecular Transport.
What is the salary of Mr Cross?
As the Chief Financial Officer of Applied Molecular Transport, the total compensation of Mr Cross at Applied Molecular Transport is $453,499. There are 3 executives at Applied Molecular Transport getting paid more, with Dr. Tahir Mahmood Ph.D. having the highest compensation of $621,009.
How old is Mr Cross?
Mr Cross is 53, he's been the Chief Financial Officer of Applied Molecular Transport since . There are 3 older and 4 younger executives at Applied Molecular Transport. The oldest executive at Applied Molecular Transport Inc. is Dr. Randall Mrsny Ph.D., 66, who is the Co-Founder, Chief Scientific Officer & Director.
What's Mr Cross's mailing address?
Shawn's mailing address filed with the SEC is C/O CYCLO THERAPEUTICS, INC., 6714 NW 16 ST., SUITE B, GAINESVILLE, FL, 32653.
Insiders trading at Applied Molecular Transport
Over the last 4 years, insiders at Applied Molecular Transport have traded over $9,673,149 worth of Applied Molecular Transport stock and bought 3,091,278 units worth $40,384,206 . The most active insiders traders include Capital Group, Llcepq Llc A..., Helen Susan Kim, and Tahir Ph.D. Mahmood. On average, Applied Molecular Transport executives and independent directors trade stock every 24 days with the average trade being worth of $26,155. The most recent stock trade was executed by Tahir Ph.D. Mahmood on 22 November 2023, trading 286,320 units of AMTI stock currently worth $45,811.
What does Applied Molecular Transport do?
Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trial for the treatment of ulcerative colitis and related inflammatory indications. It is also involved in developing AMT-126, a GI-selective oral fusion of interleukin 22, which is in a Phase Ia clinical trial for diseases related to intestinal epithelium barrier function defects. The company, through its technology platform, designs and develops various oral biologic therapeutic modalities, such as peptides, proteins, antibodies, antibody fragments, and ribonucleic acid therapeutics. Applied Molecular Transport Inc. was founded in 2010 and is headquartered in South San Francisco, California.
What does Applied Molecular Transport's logo look like?
Complete history of Mr Cross stock trades at Applied Molecular Transport and Cyclo Therapeutics
Applied Molecular Transport executives and stock owners
Applied Molecular Transport executives and other stock owners filed with the SEC include:
-
Dr. Tahir Mahmood Ph.D.,
Co-Founder, CEO & Director -
Dr. Randall Mrsny Ph.D.,
Co-Founder, Chief Scientific Officer & Director -
Elizabeth P. Bhatt M.B.A.,
Chief Bus. & Strategy Officer -
Shawn M. Cross,
Chief Financial Officer -
Graham K. Cooper,
Exec. Chairman -
Dr. Andy Whitney Ph.D.,
VP and Head of Preclinical Devel. & Translational Science -
Earl M. Douglas,
Exec. VP & Gen. Counsel -
Andrew H. Chang,
Head of Investor Relations & Corp. Communications -
Douglas A. Rich M.B.A., M.B.A,
Chief Technical Officer -
Brandon Hants,
Sr. VP of Fin. & Bus. Operations and Principal Accounting Officer -
John W Smither,
Director -
Capital Group, Llc Boeding ...,
-
Helen Susan Kim,
Director -
David Lamond,
Director -
Fund V, Lp Founders Fund V ...,
-
Tahir Ph.D. Mahmood,
Director -
Bittoo Kanwar,
Chief Medical Officer -
Aaron Van Devender,
Director -
Capital Group, Llcepq Llc A...,
-
Capital Group, Llcepq Llc A...,
-
Douglas A. Rich,
Chief Technical Officer -
Elizabeth Bhatt,
Chief Bus. & Strategy Officer -
Graham K Cooper,
Director -
Holly Caren Schachner,
Director -
Charlene A. Banard,
Director -
Shawn Cross,
CEO & Chair of the Board -
Brandon Hants,
CFO